Trump promised to clamp down on health insurers. His policies are enriching them

Finalizing higher Medicare Advantage payments for 2027 will funnel an additional $13 billion to insurers and the administration abandoned a reform that would likely have produced more accurate — and lower — payments. The move directly boosts insurers' near-term revenues and margins despite public rhetoric from President Trump and health leaders criticizing insurers. This is a sector-moving regulatory outcome that favors Medicare Advantage plans and could materially benefit major health insurers' financial results.

Analysis

The quiet policy shift in Washington structurally biases margins toward Medicare Advantage (MA) plan owners over the next 1–3 years rather than delivering a one-off windfall; management teams will likely translate incremental, recurring payment tailwinds into higher buybacks, dividends, and M&A dry powder rather than material benefit to provider economics. That capital allocation choice amplifies equity returns per dollar of revenue off the insurer side: at a fund level, a mid-single-digit uplift to MA revenue can translate into high-teens EPS leverage after cost of capital and tax, creating asymmetric upside for large, diversified players relative to smaller regional plans.

Second-order winners include MA distribution intermediaries and brokers who capture enrollment flows, PBM/retail-integrated health platforms that fold payer margin into diversified cashflows, and reinsurers/analytics vendors that monetize risk adjustment sophistication. Conversely, expect continued margin pressure on hospital systems and certain specialty providers as payers push narrower networks and more aggressive case management; medical device and high-acuity outpatient service vendors face longer sales cycles and price pushback where MA penetration is highest.

Key risks are political and accounting: a rapid shift in congressional appetite, CMS audits of risk adjustment coding, or a judicial finding could produce clawbacks or force reserve builds within months. Market re-rating is likely front-loaded around enrollment windows and quarterly earnings; absent adverse policy moves, insurer equities should reprice over a 3–12 month horizon, but events tied to elections or CMS enforcement can reverse gains inside single-digit months.

Key Decisions for Investors

• Long HUM (Humana) — buy 12-month LEAP calls (delta ~0.5–0.6) sized at 2–3% of portfolio equity exposure. Rationale: pure-play MA exposure with highest operational leverage to favorable payment footing. Target 30–50% upside in 9–12 months; hedge with 20% of notional in 3–6 month 10–15% OTM puts to protect against abrupt political reversal.
• Long UNH (UnitedHealth) — accumulate shares or a 9–12 month call spread (buy calls / sell higher strike) sized 3–4% of portfolio. Rationale: diversified payer + PBM + Optum synergy, best positioned to convert incremental MA dollars to EPS. Expect 20–35% upside over 6–12 months driven by buyback flow; downside risk ~25% in a severe policy clampdown — cap with short-dated puts representing 15–25% of position cost.
• Relative-value pair: Long large-cap insurers (UNH/HUM) / Short hospital operators (HCA) — equal notional, 6–12 month horizon. Mechanism: insurer leverage to compress provider pricing and membership migration into MA. Target relative outperformance of 10–20% over 6–12 months; risks include provider consolidation or regulatory constraints on network design that could blunt insurer bargaining power.
• Convex hedge: buy 6-month OTM puts on a basket of major insurers (representing ~20% of long exposure) or purchase short-dated single-name CDS protection if available. Purpose: inexpensive hedge against rapid policy reversal, CMS clawbacks, or litigation-driven drawdowns that can erase multi-month gains within weeks.